利妥昔单抗静脉快速输注中国专家共识 (2020 年版)

2021-01-30 中国老年保健协会 白血病·淋巴瘤.2021.30(1):1-4.

利妥昔单抗上市20多年以来,在临床实践中疗效和安全性良好。美国食品药品管理局(FDA)于2012年批准了利妥昔单抗的静脉快速输注用于第2个及后续疗程。目前,利妥昔单抗90 min静脉快速输注方案已在国

中文标题:

利妥昔单抗静脉快速输注中国专家共识 (2020 年版)

发布机构:

中国老年保健协会

发布日期:

2021-01-30

简要介绍:

利妥昔单抗上市20多年以来,在临床实践中疗效和安全性良好。美国食品药品管理局(FDA)于2012年批准了利妥昔单抗的静脉快速输注用于第2个及后续疗程。目前,利妥昔单抗90 min静脉快速输注方案已在国外成熟应用,美国国立综合癌症网络(NCCN)指南中也推荐第1个疗程利妥昔单抗输注未出现输注反应的患者,后续疗程可进行利妥昔单抗90 min静脉快速输注。我国也有研究数据证实了利妥昔单抗90 min静脉快速输注方案的安全性和耐受性。因此,基于国内外循证医学证据,为了提高患者的就诊质量以及节约医疗成本,本专家共识推荐,对于首次输注未发生明显不良反应的患者,后续疗程可使用利妥昔单抗90 min静脉快速输注方案。

相关资料下载:
[AttachmentFileName(sort=1, fileName=利妥昔单抗静脉快速输注中国专家共识(2020年版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=a73831c0020800a4, title=利妥昔单抗静脉快速输注中国专家共识 (2020 年版), enTitle=, guiderFrom=白血病·淋巴瘤.2021.30(1):1-4., authorId=0, author=, summary=利妥昔单抗上市20多年以来,在临床实践中疗效和安全性良好。美国食品药品管理局(FDA)于2012年批准了利妥昔单抗的静脉快速输注用于第2个及后续疗程。目前,利妥昔单抗90 min静脉快速输注方案已在国, cover=https://img.medsci.cn/202147/1617810685844_2020535.jpg, journalId=0, articlesId=null, associationId=1093, associationName=中国老年保健协会, associationIntro=中国老年保健协会是中华人民共和国民政部批准,国家卫生部主管的全国性社会团体,于1995年成立。该协会是由一批从事老年保健事业的医学保健专家、学者、热心老年保健工作的社会活动家、企业家和有识之士组成。协会的宗旨是:弘扬中华民族尊老、敬老、爱老的传统美德,全心全意为全社会老年人身心健康服务。, copyright=0, guiderPublishedTime=Sat Jan 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>利妥昔单抗上市20多年以来,在临床实践中疗效和安全性良好。美国食品药品管理局(FDA)于2012年批准了利妥昔单抗的静脉快速输注用于第2个及后续疗程。目前,利妥昔单抗90 min静脉快速输注方案已在国外成熟应用,美国国立综合癌症网络(NCCN)指南中也推荐第1个疗程利妥昔单抗输注未出现输注反应的患者,后续疗程可进行利妥昔单抗90 min静脉快速输注。我国也有研究数据证实了利妥昔单抗90 min静脉快速输注方案的安全性和耐受性。因此,基于国内外循证医学证据,为了提高患者的就诊质量以及节约医疗成本,本专家共识推荐,对于首次输注未发生明显不良反应的患者,后续疗程可使用利妥昔单抗90 min静脉快速输注方案。</p> </div> </div> </div>, tagList=[TagDto(tagId=1166, tagName=利妥昔单抗)], categoryList=[CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1166, guiderKeyword=利妥昔单抗, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7396, appHits=195, showAppHits=0, pcHits=1042, showPcHits=7199, likes=0, shares=9, comments=7, approvalStatus=1, publishedTime=Thu Apr 08 14:41:32 CST 2021, publishedTimeString=2021-01-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Wed Apr 07 23:51:32 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 02:21:06 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=利妥昔单抗静脉快速输注中国专家共识(2020年版).pdf)])
利妥昔单抗静脉快速输注中国专家共识(2020年版).pdf
下载请点击:
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1056542, encodeId=9bc7105654243, content=值得学习。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:31:40 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961611, encodeId=c88c9616115b, content=更加规范, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/8cccaba4e37b47ca8e152a4f732847fb/0d1d2c7e0bd7426b9ecd3318c9f11128.jpg, createdBy=14492036103, createdName=1511e8a568m, createdTime=Thu Apr 29 19:27:53 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960774, encodeId=ce4e960e7443, content=欸,积分不够了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7c5486705, createdName=ms9000001267079736, createdTime=Mon Apr 26 22:17:32 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960669, encodeId=42f99606698c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58d25483500, createdName=ms9000001532925281, createdTime=Mon Apr 26 16:01:45 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958440, encodeId=84829584402c, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Apr 19 18:36:29 CST 2021, time=2021-04-19, status=1, ipAttribution=)]
    2021-09-30 13f0c37dm61暂无昵称

    值得学习。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1056542, encodeId=9bc7105654243, content=值得学习。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:31:40 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961611, encodeId=c88c9616115b, content=更加规范, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/8cccaba4e37b47ca8e152a4f732847fb/0d1d2c7e0bd7426b9ecd3318c9f11128.jpg, createdBy=14492036103, createdName=1511e8a568m, createdTime=Thu Apr 29 19:27:53 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960774, encodeId=ce4e960e7443, content=欸,积分不够了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7c5486705, createdName=ms9000001267079736, createdTime=Mon Apr 26 22:17:32 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960669, encodeId=42f99606698c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58d25483500, createdName=ms9000001532925281, createdTime=Mon Apr 26 16:01:45 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958440, encodeId=84829584402c, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Apr 19 18:36:29 CST 2021, time=2021-04-19, status=1, ipAttribution=)]
    2021-04-29 1511e8a568m

    更加规范

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1056542, encodeId=9bc7105654243, content=值得学习。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:31:40 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961611, encodeId=c88c9616115b, content=更加规范, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/8cccaba4e37b47ca8e152a4f732847fb/0d1d2c7e0bd7426b9ecd3318c9f11128.jpg, createdBy=14492036103, createdName=1511e8a568m, createdTime=Thu Apr 29 19:27:53 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960774, encodeId=ce4e960e7443, content=欸,积分不够了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7c5486705, createdName=ms9000001267079736, createdTime=Mon Apr 26 22:17:32 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960669, encodeId=42f99606698c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58d25483500, createdName=ms9000001532925281, createdTime=Mon Apr 26 16:01:45 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958440, encodeId=84829584402c, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Apr 19 18:36:29 CST 2021, time=2021-04-19, status=1, ipAttribution=)]
    2021-04-26 ms9000001267079736

    欸,积分不够了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1056542, encodeId=9bc7105654243, content=值得学习。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:31:40 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961611, encodeId=c88c9616115b, content=更加规范, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/8cccaba4e37b47ca8e152a4f732847fb/0d1d2c7e0bd7426b9ecd3318c9f11128.jpg, createdBy=14492036103, createdName=1511e8a568m, createdTime=Thu Apr 29 19:27:53 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960774, encodeId=ce4e960e7443, content=欸,积分不够了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7c5486705, createdName=ms9000001267079736, createdTime=Mon Apr 26 22:17:32 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960669, encodeId=42f99606698c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58d25483500, createdName=ms9000001532925281, createdTime=Mon Apr 26 16:01:45 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958440, encodeId=84829584402c, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Apr 19 18:36:29 CST 2021, time=2021-04-19, status=1, ipAttribution=)]
    2021-04-26 ms9000001532925281

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1056542, encodeId=9bc7105654243, content=值得学习。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:31:40 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961611, encodeId=c88c9616115b, content=更加规范, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210506/8cccaba4e37b47ca8e152a4f732847fb/0d1d2c7e0bd7426b9ecd3318c9f11128.jpg, createdBy=14492036103, createdName=1511e8a568m, createdTime=Thu Apr 29 19:27:53 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960774, encodeId=ce4e960e7443, content=欸,积分不够了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e7c5486705, createdName=ms9000001267079736, createdTime=Mon Apr 26 22:17:32 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960669, encodeId=42f99606698c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58d25483500, createdName=ms9000001532925281, createdTime=Mon Apr 26 16:01:45 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=958440, encodeId=84829584402c, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Apr 19 18:36:29 CST 2021, time=2021-04-19, status=1, ipAttribution=)]
    2021-04-19 jyzxjiangqin

    好共识!

    0